The chairman of the board Carsten Lønfeldt and board member Marianne Weile have informed BioPorto that they resign from the board from today’s date.
Further information:
Thea Olesen, Adm. CEO
Carsten Lønfeldt
Telefon 45 29 00 00, mail investor@bioporto.com
March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 –...
Read MoreMarch 31, 2026News Release KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or...
Read More